☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Severe Eosinophilic Asthma
AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthma
October 4, 2019
GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma
September 30, 2019
GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yr...
September 13, 2019
AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma
September 18, 2018
GSK's Nucala Proves to be Superior than AZ's Fasenra and Teva's Cinqair for the Treatment of Severe Eosinophilic Asthma
September 11, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.